Back
Treatment Strategies and Safety Updates in Multiple Sclerosis
Share
Program Content
Activities
-
Treatment Strategies and Safety Updates in Multiple SclerosisVideo
Congratulations: You achieved a completion on 04/09/2022
Released: August 28, 2021
Expires: August 28, 2022
Additional Information
Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-19-300-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity. | A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities? |
Activity Description
Multiple Sclerosis (MS), often referred to as the “invisible illness”, is a debilitating and often crippling neurodegenerative disease that greatly decreases quality of life and may lead to pronounced disability. Over the last 25 years, MS treatment options have rapidly evolved and multiple safety updates for treatments were released toward the end of 2018. Clinical, specialty, and managed care pharmacists must be both familiar with and educated on treatment options, implications, and safety and access considerations for patients. Pharmacists are critically involved in the initiation, guidance, and evaluation of appropriate treatment strategies for MS. Additionally, both clinical and specialty pharmacists are positioned to identify and anticipate potential barriers to medication access and adherence, such as prior authorization submission and formulary challenges. Activities focused on the updated research and recommendations will provide pharmacists short and long-term management strategies for patients with MS and help to ensure improved overall care coordination.Learning Objectives
The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:- Outline changes within the 2018 AAN Multiple Sclerosis Practice Guidelines.
- Compare and contrast available MS treatments by patient subtype and recognize emerging therapies in the pipeline.
- Analyze updated safety insights and considerations for MS treatments.
- Identify strategies for engaging patients in education and shared decision-making to improve adherence and quality of life.
Faculty
Aimee M. Banks, PharmD, BCPS, MSCSClinical Pharmacist
Vanderbilt University Medical Center
Multiple Sclerosis Clinic
Nashville, Tennessee
Brandon M. Markley, PharmD, BCPS
Clinical Pharmacist
Vanderbilt University Medical Center
Multiple Sclerosis Clinic
Nashville, Tennessee
CE Accreditation
Release Date: August 28, 2019Expiration Date: August 28, 2022
Pharmacists
This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-300-H01-P has been assigned to this knowledge-based, home study activity (initial release date 8-28-2019). This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.Disclosure
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Aimee Banks and Brandon Markley have no relevant commercial and/or financial relationships to disclose.Funding
This activity is supported by an educational grant from Novartis.The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.